Migraine Drugs Market Size, Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities and Forecast Period
The migraine drug market is
expected to grow at a compound annual growth rate (CAGR) of 4.4% between 2024
and 2034, from an estimated size of USD 4.9 billion in 2023 to USD 7.6 billion
in 2034. Migraine medications provide a variety of individualized treatment
choices. Because of its alignment with the healthcare industry, the market is
both sustainable and expanding.
A common and serious neurological condition, migraines are
characterized by strong, recurrent headaches that are frequently accompanied by
light and sound sensitivity, nausea, and vomiting. There are four phases that
migraine symptoms can go through, affecting both adults and children: prodrome,
aura, attack, and post-drome. Both preventive/prophylactic and acute abortive
medications are used in the therapy of migraines.
Request
For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/migraine-drugs-market
GROWTH DRIVERS
The market is largely driven by the increasing prevalence
of migraines, which raises demand for efficient treatments. A JAMA Network
report states that overall, the incidence of migraines rose by 34% in men and
56% in women. Women in the 20–29 age group saw the largest increase, going from
600 to 1,000 new cases annually per 100,000 women. The NCBI reports that there
were an estimated 1.1 billion migraine cases in 2019 and that the prevalence of
migraines grew globally by 1.7% between 1990 and 2019.
The WHO and Becker report that the expense of healthcare
increased to a record high of 10.7% in 2023 from 7.4% in 2022. Globally, the
insurer-reported cost trend is expected to average 9.9% in 2024, with some
regions experiencing a more significant increase. The substantial growth in
government health spending across all national income levels is responsible for
the surge in health spending to a record high of USD 9 trillion, or over 11% of
the world's gross domestic product. The occurrence of migraines has increased
due to changes in modern lifestyle, including increased stress and screen time,
necessitating the need for better treatment.
MARKET
SEGMENTATION:
· By
Type- Acute/Abortive Treatment (Analgesic, Ergotamine, Triptans),
Preventive/P Treatment (Beta Blockers, Anti-serotonergic drugs,
anti-depressants, anticonvulsants, calcium channel blockers)
· By
Route of Administration- Oral, Injectable (Pre-filled Syringes, Vial)
· By
Distribution Channel- hospital pharmacies, retail pharmacies and online
pharmacies
· By
Region- North America, Europe, Asia Pacific, The Middle East and
Africa, South America
Global Key
Players:
· Novartis
AG
· AstraZeneca
· Amgen
Inc.
· Abbvie
· Glaxo
SmithKline plc
· Eli
Lilly and Compnany
· Abbott
Laboratories
· Teva
Pharmaceuticals Industries
· Pfizer
· Merck
& Co. Inc
· Bausch
Health Companies
· Janssen
Pharmaceutical Company
· Biohaven
Pharmaceutical Holding Company
· Endo
Pharmaceutical
· Other
Players
For
More Information about this Report @ https://www.xresearch.biz/shop/migraine-drugs-market
About
Us: -
xResearch is a
market research and consulting organization that uses unique data, expert
analysis, and new technologies to create trusted intelligence on industries.
Our research is focused on delivering an informed and impartial view on
essential market data of industry, and it is primarily driven by an in-depth
study covering the following parameters: Market Sizing and Forecasting, Market
Segmentation, Competitive Analysis, Strategic Assessment and Business
Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-619-8140
Comments
Post a Comment